WuXi AppTec Co., Ltd. (HKG:2359)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 349.89B +67.8% |
| Revenue (ttm) | 52.52B +23.4% |
| Net Income | 22.88B +80.1% |
| EPS | 7.85 +77.9% |
| Shares Out | n/a |
| PE Ratio | 15.29 |
| Forward PE | 16.98 |
| Dividend | 1.82 (1.44%) |
| Ex-Dividend Date | Sep 8, 2025 |
| Volume | 21,014,416 |
| Average Volume | 5,308,644 |
| Open | 136.10 |
| Previous Close | 126.00 |
| Day's Range | 136.00 - 148.00 |
| 52-Week Range | 56.55 - 146.50 |
| Beta | 0.54 |
| RSI | 74.13 |
| Earnings Date | Apr 27, 2026 |
About WuXi AppTec
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecula... [Read more]
Financial Performance
In 2025, WuXi AppTec's revenue was 43.42 billion, an increase of 21.40% compared to the previous year's 35.77 billion. Earnings were 19.15 billion, an increase of 102.65%.
Financial numbers in CNY Financial StatementsNews
WuXi AppTec Delivers Strong Revenue and Profit Growth in Q1 2026
Total Revenue Reached RMB 12.44 Billion; Revenue from Continuing Operations Up 39.4% YoY Adjusted Non-IFRS Net Profit Up 71.7% YoY to RMB 4.60 Billion Backlog for Continuing Operations Up 23.6% YoY to...
WuXi AppTec Earnings Call Transcript: H2 2025
Record 2025 results with revenue up 21.4% and adjusted net profit up 41.3% year-over-year. 2026 guidance targets 18–22% revenue growth, robust cash flow, and continued global expansion, supported by a strong backlog and resilient business model.
WuXi AppTec Beat Full-Year Guidance and Achieved Record Performance in 2025
2025 Total Revenue Reached RMB 45.46 Billion; Revenue from Continuing Operations Up 21.4% YoY Adjusted Non-IFRS Net Profit Up 41.3% YoY to RMB 14.96 Billion Backlog for Continuing Operations Up 28.8% ...
WuXi AppTec Receives Double "A" Rating from CDP for Climate Change and Water Security Leadership
SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced that it has been recognized...
WuXi AppTec Transcript: 44th Annual J.P. Morgan Healthcare Conference
Record 2025 revenue and profit were driven by strong demand in GLP-1, peptides, and small molecules, with significant capacity expansions and robust global customer growth. The company maintained high ESG standards, returned substantial value to shareholders, and expects continued growth in 2026.
WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Award in the CRDMO Industry
SHANGHAI, MIDDLETOWN, Del. and MUNICH , Nov. 19, 2025 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been reco...
China's Corporate Pivots: Alibaba's Food Delivery Gambit and WuXi AppTec's Geopolitical Hedge
Two recent, seemingly unrelated corporate maneuvers offer a telling glimpse into the strategic pivots major Chinese companies are making in response to shifting consumer habits and global political cu...
WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health
SHANGHAI , Oct. 28, 2025 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced it has signed two strategi...
WuXi AppTec Earnings Call Transcript: Q3 2025
Record revenue and profit growth in the first three quarters, driven by strong performance in small molecule and TIDES businesses, with robust backlog and improved margins. Raised full-year guidance, accelerated global expansion, and announced divestiture of China-based clinical research services.
WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance
SHANGHAI, Oct. 26, 2025 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pha...
WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends
SHANGHAI, Sept. 21, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies ...
WuXi AppTec Awarded Gold Medal by EcoVadis Sustainability Rating for Second Consecutive Year
SHANGHAI , Sept. 8, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indu...
WuXi AppTec Completes Second RMB1.0 Billion A-Share Repurchase Program in 2025, All Repurchased Shares to Be Cancelled
SHANGHAI , Aug. 27, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies ...
WuXi AppTec Named Constituent of the FTSE4Good Index Series for Third Consecutive Year
SHANGHAI , Aug. 5, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indus...
China's Wuxi Apptec to raise over $980 million to boost expansion
Wuxi Apptec said on Thursday it will be raising HK$7.70 billion ($980.98 million) through a share placement to aid its global expansion plans.
WuXi AppTec Earnings Call Transcript: H1 2025
Record first-half revenue and profit driven by strong CRDMO growth, margin expansion, and robust U.S. demand. Full-year guidance was raised, with significant capital returns to shareholders and continued global capacity expansion planned.
WuXi AppTec Achieves Strong Growth in Revenue and Profit for Q2 and H1 2025, H1 Revenue from Continuing Operations[1] Up 24.2% YoY, and Adjusted Non-IFRS Net Profit Up 44.4% YoY; Backlog for Continuing Operations Up 37.2% YoY
Total Revenue Reached RMB11.14 Billion in the Second Quarter, Up 20.4% Year-over-Year; among which Revenue from Continuing Operations Reached RMB11.05 Billion, Up 24.9% Year-over-Year Total Revenue Re...
WuXi AppTec Issues Positive Profit Alert for the First Half of 2025
SHANGHAI , July 10, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH/2359.HK), a leading global pharmaceutical and life sciences technology platform company offering integrated, end-t...
WuXi AppTec Provides Updates on Q2 Share Repurchase/Acquisition Activities
SHANGHAI , July 7, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies i...
WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity
SHANGHAI , June 26, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indu...
WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets
SHANGHAI , June 17, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indu...
Focus: China pharma projects disrupted by Sino-US tensions
Drug research and development firms in China including WuXi AppTec and WuXi Biologics are changing project plans, stockpiling supplies and discussing testing locally, said sources with knowledge of th...
WuXi AppTec Recognized by Extel 2025 Asia Executive Team Rankings with Top Honors
SHANGHAI , June 16, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science indu...
WuXi AppTec Q1 2025 Revenue, Profit Resume Double Digit Growth, Revenue Up 21.0% YoY, Adjusted Non-IFRS Net Profit Up 40.0% YoY; Backlog for Continuing Operations Up 47.1% YoY
Total Revenue Reached RMB9.65 Billion, Up 21.0% Year-over-Year; among which Revenue from Continuing Operations Reached RMB9.39 Billion, Up 23.1% Year-over-Year Net Profit Attributable to the Owners of...
WuXi AppTec Earnings Call Transcript: Q1 2025
Q1 2025 saw double-digit revenue and profit growth, with strong performance in Chemistry and TIDES segments, while Testing faced pricing pressure. Full-year guidance is maintained despite global uncertainties, with robust capital allocation and continued expansion in key markets.